"Have You Seen This?" Bone Anti-Resorptive Properties of Bisphosphonates Design: Twenty-eight-day-old male Sprague-Dawley rats were given a bisphosphonate compound subcutaneously for 7 days. The right tibia was fixed in 70% ethanol, embedded in methylmethacrylate, sectioned undecalcified, and stained with Toluidine blue.
Results: The primary spongiosa is not remodeled, as shown in the comparison of normal ( Fig. 1 ) and treated ( Fig. 2) animals, causing hyperostosis of the proximal tibial metaphysis. Higher magnification of another treated animal (Fig. 3 ) shows the pale purple mineralized bone that has been deposited over the deep purple retained cartilage cores. bone resorption, through inhibition of osteoclast function. In a young, growing animal, metaphyseal changes are similar in appearance to osteopetrosis, which is characterized by deficient resorption of spongiosa and remodeling/modeling deficits. Note that in contrast to resorption of spongiosa, the resorption of cartilage below the hypertrophic zone of the growth plate is normal (as in hereditary osteopetrosis). This observation supports the concept that cartilage resorption may be mediated by vascular in-growth rather than by osteoclasts/chondroclasts. The dose-response prevention of primary spongiosa resorption is used to quantify bisphosphonate potency. Bisphosphonates are analogs of pyrophosphate and, as a class, inhibit osteoclastic resorption and remodeling of bone. In bisphosphonates, the oxygen in the phosphorous-oxygen bond of pyrophosphate (P-O-P) has been replaced with a carbon, creating a phosphorus-carbon bond (P-C-P), which is poorly metabolized. Side chains attached to the central carbon alter properties such as anti-mineralization and anti-resorption activity. Bisphosphonates have a high affinity for mineralized tissue and are incorporated on any exposed bone surface. This specific targeting to osteoclast resorption pits and/or mineralizing bone surfaces provides high local concentrations at the desired site of action. The cellular mechanism of action of bisphosphonates is currently unknown. Bisphosphonates are used in the treatment of accelerated bone turnover diseases, and are approved for treatment of osteoporosis, Paget's disease, and heterotopic ossification. 
Discussion: Bisphosphonate administration prevents

